Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation

Yo Hoshino, Hiroshi Kimura, Naoko Tanaka, Ikuya Tsuge, Kazuko Kudo, Keizo Horibe, Koji Kato, Takaharu Matsuyama, Atsushi Kikuta, Seiji Kojima, Tsuneo Morishima

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV)-related lymphoproliferative disorder (LPD) is a serious complication of haematopoietic stem cell transplantation (HSCT). To clarify the frequency, natural course and risk factors for LPD, we prospectively monitored 38 allogeneic (allo)-HSCT patients, focusing on the use of anti-thymocyte globulin (ATG). We used a recently developed real-time polymerase chain reaction assay to monitor EBV genome load. The subjects consisted of 19 patients given ATG for conditioning and 19 patients not given ATG. Of the 19 patients given ATG, 47.4% (nine patients) had a significant increase in EBV genome load (102.5 copies/μg DNA). Of these nine patients, two developed LPD. Therefore, 10.5% of the patients receiving allo-HSCT with ATG developed LPD. In contrast, none of the 19 patients without ATG had a significantly increased EBV load. The increases in viral load were observed in the second or third month after HSCT. We found that the peak viral loads of LPD patients were > 104.0 copies/μg DNA. On the other hand, the viral loads of most patients with no symptoms were < 102.5 copies/μg DNA. In conclusion, routine monitoring of EBV load during the second and third months after transplantation may benefit patients undergoing HSCT with ATG. We propose that an EBV load > 102.5 copies/μg DNA is the reactivation of EBV, and that an EBV load > 104.0 copies/μg DNA is indicative of developing LPD.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalBritish Journal of Haematology
Volume115
Issue number1
DOIs
Publication statusPublished - Nov 6 2001

Fingerprint

Stem Cell Transplantation
Human Herpesvirus 4
Real-Time Polymerase Chain Reaction
Antilymphocyte Serum
Lymphoproliferative Disorders
DNA
Hematopoietic Stem Cell Transplantation
Viral Load
Genome

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. / Hoshino, Yo; Kimura, Hiroshi; Tanaka, Naoko; Tsuge, Ikuya; Kudo, Kazuko; Horibe, Keizo; Kato, Koji; Matsuyama, Takaharu; Kikuta, Atsushi; Kojima, Seiji; Morishima, Tsuneo.

In: British Journal of Haematology, Vol. 115, No. 1, 06.11.2001, p. 105-111.

Research output: Contribution to journalArticle

Hoshino, Yo ; Kimura, Hiroshi ; Tanaka, Naoko ; Tsuge, Ikuya ; Kudo, Kazuko ; Horibe, Keizo ; Kato, Koji ; Matsuyama, Takaharu ; Kikuta, Atsushi ; Kojima, Seiji ; Morishima, Tsuneo. / Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. In: British Journal of Haematology. 2001 ; Vol. 115, No. 1. pp. 105-111.
@article{f31bbd38067f4a8393f8b881a5830dce,
title = "Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation",
abstract = "Epstein-Barr virus (EBV)-related lymphoproliferative disorder (LPD) is a serious complication of haematopoietic stem cell transplantation (HSCT). To clarify the frequency, natural course and risk factors for LPD, we prospectively monitored 38 allogeneic (allo)-HSCT patients, focusing on the use of anti-thymocyte globulin (ATG). We used a recently developed real-time polymerase chain reaction assay to monitor EBV genome load. The subjects consisted of 19 patients given ATG for conditioning and 19 patients not given ATG. Of the 19 patients given ATG, 47.4{\%} (nine patients) had a significant increase in EBV genome load (102.5 copies/μg DNA). Of these nine patients, two developed LPD. Therefore, 10.5{\%} of the patients receiving allo-HSCT with ATG developed LPD. In contrast, none of the 19 patients without ATG had a significantly increased EBV load. The increases in viral load were observed in the second or third month after HSCT. We found that the peak viral loads of LPD patients were > 104.0 copies/μg DNA. On the other hand, the viral loads of most patients with no symptoms were < 102.5 copies/μg DNA. In conclusion, routine monitoring of EBV load during the second and third months after transplantation may benefit patients undergoing HSCT with ATG. We propose that an EBV load > 102.5 copies/μg DNA is the reactivation of EBV, and that an EBV load > 104.0 copies/μg DNA is indicative of developing LPD.",
author = "Yo Hoshino and Hiroshi Kimura and Naoko Tanaka and Ikuya Tsuge and Kazuko Kudo and Keizo Horibe and Koji Kato and Takaharu Matsuyama and Atsushi Kikuta and Seiji Kojima and Tsuneo Morishima",
year = "2001",
month = "11",
day = "6",
doi = "10.1046/j.1365-2141.2001.03087.x",
language = "English",
volume = "115",
pages = "105--111",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation

AU - Hoshino, Yo

AU - Kimura, Hiroshi

AU - Tanaka, Naoko

AU - Tsuge, Ikuya

AU - Kudo, Kazuko

AU - Horibe, Keizo

AU - Kato, Koji

AU - Matsuyama, Takaharu

AU - Kikuta, Atsushi

AU - Kojima, Seiji

AU - Morishima, Tsuneo

PY - 2001/11/6

Y1 - 2001/11/6

N2 - Epstein-Barr virus (EBV)-related lymphoproliferative disorder (LPD) is a serious complication of haematopoietic stem cell transplantation (HSCT). To clarify the frequency, natural course and risk factors for LPD, we prospectively monitored 38 allogeneic (allo)-HSCT patients, focusing on the use of anti-thymocyte globulin (ATG). We used a recently developed real-time polymerase chain reaction assay to monitor EBV genome load. The subjects consisted of 19 patients given ATG for conditioning and 19 patients not given ATG. Of the 19 patients given ATG, 47.4% (nine patients) had a significant increase in EBV genome load (102.5 copies/μg DNA). Of these nine patients, two developed LPD. Therefore, 10.5% of the patients receiving allo-HSCT with ATG developed LPD. In contrast, none of the 19 patients without ATG had a significantly increased EBV load. The increases in viral load were observed in the second or third month after HSCT. We found that the peak viral loads of LPD patients were > 104.0 copies/μg DNA. On the other hand, the viral loads of most patients with no symptoms were < 102.5 copies/μg DNA. In conclusion, routine monitoring of EBV load during the second and third months after transplantation may benefit patients undergoing HSCT with ATG. We propose that an EBV load > 102.5 copies/μg DNA is the reactivation of EBV, and that an EBV load > 104.0 copies/μg DNA is indicative of developing LPD.

AB - Epstein-Barr virus (EBV)-related lymphoproliferative disorder (LPD) is a serious complication of haematopoietic stem cell transplantation (HSCT). To clarify the frequency, natural course and risk factors for LPD, we prospectively monitored 38 allogeneic (allo)-HSCT patients, focusing on the use of anti-thymocyte globulin (ATG). We used a recently developed real-time polymerase chain reaction assay to monitor EBV genome load. The subjects consisted of 19 patients given ATG for conditioning and 19 patients not given ATG. Of the 19 patients given ATG, 47.4% (nine patients) had a significant increase in EBV genome load (102.5 copies/μg DNA). Of these nine patients, two developed LPD. Therefore, 10.5% of the patients receiving allo-HSCT with ATG developed LPD. In contrast, none of the 19 patients without ATG had a significantly increased EBV load. The increases in viral load were observed in the second or third month after HSCT. We found that the peak viral loads of LPD patients were > 104.0 copies/μg DNA. On the other hand, the viral loads of most patients with no symptoms were < 102.5 copies/μg DNA. In conclusion, routine monitoring of EBV load during the second and third months after transplantation may benefit patients undergoing HSCT with ATG. We propose that an EBV load > 102.5 copies/μg DNA is the reactivation of EBV, and that an EBV load > 104.0 copies/μg DNA is indicative of developing LPD.

UR - http://www.scopus.com/inward/record.url?scp=0034773061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034773061&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.03087.x

DO - 10.1046/j.1365-2141.2001.03087.x

M3 - Article

C2 - 11722419

AN - SCOPUS:0034773061

VL - 115

SP - 105

EP - 111

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -